ClinicalTrials.Veeva

Menu

LEC Proliferation in Vivo and In-vitro

P

Prim. Prof. Dr. Oliver Findl, MBA

Status

Unknown

Conditions

Posterior Capsule Opacification

Treatments

Procedure: In-vitro model

Study type

Observational

Funder types

Other

Identifiers

NCT03857685
Proliferation

Details and patient eligibility

About

Investigate the proliferative capacity of individual lens epithelium capsule specimens in vitro and correlate it to the risk of developing PCO

Full description

Cataract, the clouding of the eye's lens, is still the leading cause of blindness worldwide. Until now surgery is the only therapy available for the disease. Cataract surgery is nowadays considered a safe and efficient therapy. However, one of the most frequent complications of cataract surgery is posterior capsule opacification (PCO), which results in diminished postoperative visual acuity. PCO occurs due to a robust wound-healing response, where remaining lens epithelial cells in the capsular bag start to migrate and proliferate.

The lens capsule is divided into an anterior, an equatorial, and a posterior region. The anterior and the equatorial region consist of a single layer of cuboidal epithelial cells, whilst the posterior region is formed of fibers. In the adult lens proliferation occurs almost exclusively in the equatorial region and although the central part of the lens epithelium exhibits very low mitotic activity, it was shown in experiments that cell in this area are also stem cells. There are three possible reasons for the generation of PCO: intraoperative factors (dependening on the amount of remaining cells in the capsular bag), intraocular lens factors, and interpersonal factor (patient-specific factors).

Aim of this study is the generation of an in-vitro model of posterior capsule opacification. Therefore, the investigators will analyse the proliferative capacity of lens epithelial cells on the lens capsule, which is removed during cataract surgery, in a cell culture model. The investigators then compare the proliferative capacity between young and old patients, between both eyes of the same patient, and in different forms of cataract.

Enrollment

40 estimated patients

Sex

All

Ages

21 to 105 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age-related cataract.
  • Patients in the age group of 21 years and older.
  • Patients with uncomplicated cataract.
  • Patients without any relevant systemic or ocular morbidity.
  • Patients with well dilating pupils.
  • Written informed consent prior to any study specific action.

Exclusion criteria

  • Patients with complicated cataract.
  • Patients with big differences in LOCS scale between the two eyes.
  • Patients having corneal pathology.
  • Patients with any form of ocular inflammation.
  • Patients with glaucoma, retinal pathologies.
  • Patients with traumatic cataracts, subluxated and dislocated lens, prior h/o ocular surgery, pseudoexfoliation.
  • Any intraoperative complications like posterior capsule rupture.
  • In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age).

Trial design

40 participants in 1 patient group

Proliferation in an in-vitro model
Description:
An in-vitro model is used to study lens epithelial cell proliferation
Treatment:
Procedure: In-vitro model

Trial contacts and locations

1

Loading...

Central trial contact

Manuel Ruiß, MSc.; Andreea Fisus, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems